

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES  
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

## 144: Filer Information

Filer CIK 0001801917  
Filer CCC XXXXXXXXX  
Is this a LIVE or TEST Filing?  LIVE  TEST

### Submission Contact Information

Name  
Phone  
E-Mail Address

## 144: Issuer Information

Name of Issuer Roivant Sciences Ltd.  
SEC File Number 001-40782  
Address of Issuer c/o Roivant Sciences Ltd., 7th floor  
50 Broadway  
London  
UNITED KINGDOM  
SW1H 0DB  
Phone 44207 400 3347  
Name of Person for Whose Account the Securities are To Be Sold Venker Eric

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer

## 144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	Rockefeller Financial LLC 45 Rockefeller Plaza - Floor 5 New York NY 10111	238724	2204059.84	758427350	05/09/2023	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

## 144: Securities To Be Sold

Title of the	Date you	Nature of	Name of	Is	Date	Amount of	Date of	Nature of
--------------	----------	-----------	---------	----	------	-----------	---------	-----------

Class	Acquired	Acquisition Transaction	Person from Whom Acquired	this a Gift?	Donor Acquired	Securities Acquired	Payment	Payment *
Common	05/09/2023	Options Exercise - Grant Date 4/20/2022	Roivant Sciences Ltd.	<input type="checkbox"/>		238724	05/09/2023	Wire

\* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB	Common	02/21/2023	28939	249454.18
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	common	03/20/2023	28936	252032.56
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 broadway london X0 SW1H 0DB	common	04/26/2023	72906	631675.25
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	73,514	04/27/2023	73514	625908.88
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	common	04/28/2023	75823	641877.24
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	common	05/01/2023	61155	525251.75
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	common	05/02/2023	109074	897477.32
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	common	05/03/2023	118760	997196.40
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	common	05/04/2023	88838	737504.16
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	common	05/08/2023	61206	546237.33

# 144: Remarks and Signature

Remarks

Date of Notice 05/09/2023

Date of Plan Adoption or Giving of Instruction, 02/25/2023  
If Relying on Rule 10b5-1

**ATTENTION:**

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature Jason Coleman as a duly authorized representative of National Financial Services LLC, as attorney-in-fact for Eric Venker

**ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)**